Skip to content

Lgnd stock zacks

Lgnd stock zacks

Ligand Pharmaceuticals Incorporated is a company in the U.S. stock market and it is a holding in 72 U.S.-traded ETFs. LGND has around 2.5M shares in the U.S. ETF market. Ligand (LGND) Stock Down Despite Q2 Earnings & Sales ... Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reported second-quarter 2019 adjusted earnings of 68 cents per share, which beat the Zacks Consensus Estimate of 61 cents.The company had Zacks: Analysts Anticipate Ligand Pharmaceuticals Inc ... Equities analysts expect Ligand Pharmaceuticals Inc. (NASDAQ:LGND) to post earnings of $0.61 per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Ligand Pharmaceuticals’ earnings. Ligand Pharmaceuticals reported earnings of $1.16 per share during the same quarter last year, which suggests a negative year over year growth rate of 47.4%. Ligand (LGND) Surges: Stock Moves 6.3% Higher | Stocks Analysis by Zacks Investment Research covering: S&P 500, Acorda Therapeutics Inc, Ligand Pharmaceuticals Incorporated. Read Zacks Investment Research's latest article on

2019-07-23 - Wall Street expects a year-over-year decline in earnings on lower revenues when Ligand Pharmaceuticals (LGND - Free Report) reports 

Should Value Investors Buy Ligand Pharmaceuticals (LGND) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Ligand Pharmaceuticals - 28 Year Stock Split History | LGND Sector Industry Market Cap Revenue; Medical: Medical - Biomedical and Genetics: $1.582B: $0.120B: Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory … ETFs Holding LGND | Ligand Pharmaceuticals Inc | ETF Channel

Ligand (LGND) Up 16.3% Since Last Earnings Report: Can It Continue? From Zacks Investment Research Mar 7, 2020 Ligand (LGND) reported earnings 30 days ago.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report To read this article on click here. LGND is currently sporting a Zacks Rank of #1 (Strong Buy) and an A for Value. Investors should also recognize that LGND has a P/B ratio of 2.49. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities.

Given that the stocks previous close was at 0.94 this now indicates there is a potential with ticker code (WATT) have now 2 analysts in total covering the stock.

Sep 13, 2019 LGND News: Earnings, Analyst Moves, and More

Analysts Estimate Ligand Pharmaceuticals (LGND) to Report ...

Is the Options Market Predicting a Spike in Ligand (LGND) Stock? by Zacks Equity Research Published on April 09,2020 . Investors need to pay close attention to Ligand (LGND) stock based on the

Apex Business WordPress Theme | Designed by Crafthemes